Cytokinetics, Inc. (CYTK) announced the publication of its Phase II Evidence of Effect clinical study of CK-2017357, an orally bioavailable fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis, or ALS.
The results showed that single oral doses of 250 mg and 500 mg of CK-2017357 appeared safe and well-tolerated in patients with ALS that were studied. In addition, measures of muscle endurance appeared to be improved in a dose-related fashion in patients who received CK-2017357. Also, patients who received CK-2017357, and their investigators, perceived a global benefit on treatment.
The company noted that data from the study, which compared single doses of CK-2017357 to placebo, informed the design of subsequent studies conducted by it which have assessed the safety and tolerability of CK-2017357 in other dosing regimens.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.